Azer-Cel Safety Profile was Significantly Improved Compared to Prior Cohorts in Patients Dosed Using Optimized Product at Lower Intensity Lymphodepletion; No Grade 3 or Greater Allogeneic CAR T. | May 31, 2023
- Program Updates Planned for Azer-cel and PBCAR19B in May 2023
- Presented data on PBGENE-HBV program at Global Hepatitis Summit 2023; PBGENE-DMD program data update upcoming at ASGCT. | May 9, 2023
Redwood Wealth Management Group LLC bought a new position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 174,735 shares of the company’s stock, valued at approximately $208,000. Redwood Wealth […]
Precision BioSciences, Inc. , a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has received a Notice. | April 13, 2023
Precision BioSciences, Inc. (NASDAQ:DTIL – Get Rating) CEO Michael Amoroso sold 46,999 shares of the firm’s stock in a transaction dated Wednesday, March 22nd. The stock was sold at an average price of $0.82, for a total value of $38,539.18. Following the completion of the transaction, the chief executive officer now directly owns 68,738 shares […]